Literature DB >> 6325253

The polymorphic paraoxonase/arylesterase isozymes of human serum.

B N La Du, H W Eckerson.   

Abstract

There is now considerable evidence that human serum contains an enzyme with both paraoxonase and arylesterase activities. The enzyme probably exists in two common isozymic forms with qualitatively distinctive properties. These isozymes differ particularly in their ratio of paraoxonase /arylesterase activities, one form having a ratio approximately seven times greater than the other. By measuring paraoxonase activity in the presence of 1 M NaCl, and arylesterase activity with phenylacetate under standard conditions, it is possible to classify individuals within one of the three phenotypes determined by a two-allele, single autosomal locus system at the ESA locus. These alleles are designated ESA*A and ESA*B. Pedigree analyses have also shown the anticipated Mendelian segregation of these traits within families. The frequencies of the ESA*A and ESA*B alleles in a sample population of unrelated Caucasian people in the United States were estimated to be 0.685 and 0.315, respectively, for the traits conferring relatively low and high paraoxonase activities. It still remains to be determined whether the distinctive phenotypes affect the degree of sensitivity or resistance to organophosphate agents, such as paraoxon. We do not know what additional functions these polymorphic enzymes may have in the metabolism of other compounds, particularly those of endogenous origin.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6325253

Source DB:  PubMed          Journal:  Fed Proc        ISSN: 0014-9446


  15 in total

1.  Distinction between 'A'-esterases and arylesterases. Implications for esterase classification.

Authors:  M I Mackness; H M Thompson; A R Hardy; C H Walker
Journal:  Biochem J       Date:  1987-07-01       Impact factor: 3.857

2.  Ciprofibrate increases paraoxonase activity in patients with metabolic syndrome.

Authors:  György Paragh; Ildikó Seres; Mariann Harangi; Annamária Erdei; Mária Audikovszky; Lóránd Debreczeni; Anna Kovácsay; László Illyés; Gyula Pados
Journal:  Br J Clin Pharmacol       Date:  2006-06       Impact factor: 4.335

Review 3.  From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions.

Authors:  Daniel W Nebert; Ge Zhang; Elliot S Vesell
Journal:  Drug Metab Rev       Date:  2008       Impact factor: 4.518

4.  Characterization of human paraoxonase 1 variants suggest that His residues at 115 and 134 positions are not always needed for the lactonase/arylesterase activities of the enzyme.

Authors:  Priyanka Bajaj; Rajan K Tripathy; Geetika Aggarwal; Abhay H Pande
Journal:  Protein Sci       Date:  2013-10-26       Impact factor: 6.725

5.  Activity of esterases in plasma from Ghanaian and British subjects.

Authors:  F M Williams; E N Nicholson; N W Woolhouse; K K Adjepon-Yamoah; M D Rawlins
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

6.  Paraoxonase and arylesterase levels in rheumatoid arthritis.

Authors:  A Isik; S S Koca; B Ustundag; H Celik; A Yildirim
Journal:  Clin Rheumatol       Date:  2006-04-27       Impact factor: 2.980

7.  Role of renal metabolism and excretion in 5-nitrofuran-induced uroepithelial cancer in the rat.

Authors:  L A Spry; T V Zenser; S M Cohen; B B Davis
Journal:  J Clin Invest       Date:  1985-09       Impact factor: 14.808

Review 8.  "A" esterases and their role in regulating the toxicity of organophosphates.

Authors:  C H Walker; M I Mackness
Journal:  Arch Toxicol       Date:  1987       Impact factor: 5.153

9.  The human paraoxonase-1 phenotype modifies the effect of statins on paraoxonase activity and lipid parameters.

Authors:  Hossein Z Mirdamadi; Ferenc Sztanek; Zoltan Derdak; Ildiko Seres; Mariann Harangi; György Paragh
Journal:  Br J Clin Pharmacol       Date:  2008-09       Impact factor: 4.335

10.  Activity of Paraoxonase/Arylesterase and Butyrylcholinesterase in Peripheral Blood of Gulf War Era Veterans With Neurologic Symptom Complexes or Post-Traumatic Stress Disorder.

Authors:  David D Haines; John E Ottenweller; Benjamin F Dickens; Fadia Fouad Mahmoud; Paul H Levine
Journal:  J Occup Environ Med       Date:  2017-10       Impact factor: 2.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.